Literature DB >> 5937995

Vascular status of patients who have cholesterol emboli in the retina.

R W Hollenhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5937995     DOI： 10.1016/0002-9394(66)90238-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  8 in total

1.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

2.  Prevalence and associations of asymptomatic retinal emboli in Latinos: the Los Angeles Latino Eye Study (LALES).

Authors:  Susan Liu Hoki; Rohit Varma; Mei Ying Lai; Stanley P Azen; Ronald Klein
Journal:  Am J Ophthalmol       Date:  2007-11-05       Impact factor: 5.258

3.  Morbidity and survivorship of patients with embolic cholesterol crystals in the ocular fundus.

Authors:  D D Pfaffenbach; R W Hollenhorst
Journal:  Trans Am Ophthalmol Soc       Date:  1972

Review 4.  Plasminogen activators and ischemic stroke: conditions for acute delivery.

Authors:  Gregory J del Zoppo
Journal:  Semin Thromb Hemost       Date:  2013-03-28       Impact factor: 4.180

5.  Retinal emboli and cardiovascular disease: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Barbara E K Klein; Scot E Moss; Stacy M Meuer
Journal:  Trans Am Ophthalmol Soc       Date:  2003

6.  Prognosis of patients with retinal embolism.

Authors:  R S Howard; R W Russell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-09       Impact factor: 10.154

7.  Atheromatous embolic disease.

Authors:  H Schipper; M Gordon; B Berris
Journal:  Can Med Assoc J       Date:  1975-10-04       Impact factor: 8.262

Review 8.  Hemostasis and alterations of the central nervous system.

Authors:  Gregory J del Zoppo; Yoshikane Izawa; Brian T Hawkins
Journal:  Semin Thromb Hemost       Date:  2013-10-28       Impact factor: 4.180
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.